Press Releases
2023
- Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders 14 November 2023
- “Autifony provides an update to the National Fragile X Foundation on our research programme in Fragile X Syndrome” 4 October 2023
- Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7) 13 June 2023
2022
- Autifony to present preclinical data supporting the efficacy of its novel clinical-stage Kv3 modulators to address cellular dysfunction, ataxia, and seizure susceptibility in PME (Progressive Myoclonic Epilepsy, EPM7) at the American Epilepsy Society (AES) Annual Meeting, taking place 2-6 December 2022 in Nashville, Tennessee 7 October 2022
- Autifony and collaborators publish the results from a clinical trial of AUT00206 in patients with schizophrenia. 3 October 2022
- Autifony to speak at the Schizophrenia International Research Society (SIRS) meeting in Florence 6 – 10th April 21 March 2022
2021
- Autifony to speak at ‘Fragile X syndrome webinar – in pursuit of a cure’ World Fragile X Day 1 May 2021
- Autifony presents key efficacy data for AUT00206 from a first-in-patient safety/PK study in patients with schizophrenia at the Schizophrenia International Research Society annual meeting 16 April 2021
- Autifony Therapeutics, Boehringer Ingelheim to collaborate on novel ion channel target with potential in multiple disease areas related to lysosomal storage disorders 4 March 2021
2019
- Autifony Therapeutics achieves second milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders 30 May 2019
- Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator 11 April 2019
- Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders 18 January 2019
2017
- Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders 18 December 2017
- Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome 10 July 2017
- Autifony Therapeutics initiates recruitment into schizophrenia clinical trial for first-in-class drug 18 May 2017
- Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia 15 March 2017
- Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia 10 January 2017
2016
- Autifony Announces Results from Completed CLARITY-1, Phase IIa Trial of AUT00063 in Age-related Hearing Loss 9 August 2016
- Autifony Therapeutics successfully completes Phase I study of AUT00206, a first-in-class Kv3 modulator for schizophrenia 1 August 2016
- Autifony Therapeutics initiates QuicK+fire, a pilot study of AUT00063 in adult cochlear implant users 6 July 2016
- Update from Autifony Therapeutics’ QUIET-1 tinnitus clinical trial 28 April 2016
2015
- Autifony Therapeutics initiates Phase I study of AUT00206, a novel treatment approach for schizophrenia 24 November 2015
- Update from Autifony Therapeutics’ QUIET-1 clinical trial 13 October 2015
- Dr John Hutchison joins Autifony Therapeutics as Chief Medical Officer 3 September 2015
- Autifony Therapeutics extends Series A with £8 million for hearing disorders and schizophrenia clinical trials 10 July 2015
- Autifony Therapeutics recruits first patient into Phase IIa trial for first-in-class drug to treat Age Related Hearing Loss. Study follows acceptance of Autifony’s first IND by the FDA 27 April 2015
- Autifony Therapeutics announces £3.3 million collaboration to progress first-in-class drug for schizophrenia into clinical trials 16 April 2015
2014
- Autifony Therapeutics announces initiation of Phase IIa study for first-in-class drug to treat tinnitus 20 November 2014
- Autifony Therapeutics supports art exhibition ‘Reassembling the self’, focused on schizophrenia, together with Universities of Manchester and Newcastle 16 September 2014
- Autifony Therapeutics shortlisted in top five biotech SMEs in Europe by EuropaBio 1 September 2014
- Autifony Therapeutics hosts symposium ‘Schizophrenia: a treatable brain disorder’ at British Association for Psychopharmacology 21 July 2014
- Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study 4 June 2014
2013
- Autifony Therapeutics wins Best Emerging Biotech Award at OBN Awards Dinner 2 October 2013
- Autifony Therapeutics Announces £2.75m Collaboration with Universities of Manchester and Newcastle to Progress a First-in-Class Drug for Schizophrenia 1 July 2013
- Autifony Therapeutics Initiates Phase I Study for Lead Product, AUT00063, for the Treatment of Hearing Loss and Tinnitus and Tops Up Series A Financing with Further 5.5 million Investment 4 June 2013
2012
- ‘The Abandoned Illness’ a report by the Schizophrenia Commission 14 November 2012
Filter
- All
- 2023
- 2022
- 2021
- 2020
- 2019
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012